Volume 2.30 | Aug 2

Hematopoiesis News 2.30, August 2, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Hematopoiesis News on Twitter

Deletion of Tet2 in Mice Leads to Dysregulated Hematopoietic Stem Cells and Subsequent Development of Myeloid Malignancies
To study the function of TET2 in vivo, researchers generated a Tet2 knock out mouse model. [Blood]



Scientists Reveal Mechanism Behind ‘Oncogene Addiction’ in Acute Leukemia
A team of scientists has laid bare the mechanism behind a phenomenon called oncogene addiction in mice suffering from a form of leukemia that mimics acute myelogenous leukemia in humans. [Press release from Cold Spring Harbor Laboratory discussing online prepublication in Genes & Development]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Reduced Production of B-1–Specified Common Lymphoid Progenitors Results in Diminished Potential of Adult Marrow to Generate B-1 Cells
To address the B-1B cell production controversy, investigators compared the efficiency with which hematopoietic stem cells and common lymphoid progenitors (CLPs) from neonates and adults generated B-1 cells in vivo and developed a clonal in vitro assay to quantify B-1 progenitor production from CLPs. [Proc Natl Acad Sci U S A]

Arsenic Disulfide Synergizes with the Phosphoinositide 3-Kinase Inhibitor PI-103 to Eradicate Acute Myeloid Leukemia Stem Cells by Inducing Differentiation
Investigators explored a novel combination approach to enhance the eradication of leukemia stem cells by arsenic in non- acute promyelocytic leukemia. [Carcinogenesis]

Aryl Hydrocarbon Receptor Activation in Hematopoietic Stem/Progenitor Cells Alters Cell Function and Pathway-Specific Gene Modulation Reflecting Changes in Cellular Trafficking and Migration
In this study, scientists tested the hypothesis that 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated phenotypic and functional changes of hematopoietic stem cells are a result of changes in gene expression that disrupt stem cell numbers and/or their migration. [Mol Pharmacol]

Effects of Stem Cell Factor on Hypoxia-Inducible Factor 1 Alpha Accumulation in Human Acute Myeloid Leukemia and LAD2 Mast Cells
Here researchers show that stem cell factor induces hypoxia-inducible factor 1α accumulation in THP-1 human myeloid leukemia cells but not in LAD2 mast cells. [PLoS One]


Autologous Non-Myeloablative Hematopoietic Stem-Cell Transplantation Compared with Pulse Cyclophosphamide Once Per Month for Systemic Sclerosis (ASSIST): An Open-Label, Randomized Phase II Trial
Investigators aimed to assess safety and efficacy of autologous non-myeloablative hematopoietic stem-cell transplantation in a Phase II trial compared with the standard of care, cyclophosphamide. [Lancet]

Outcomes of a 1-Day Nonmyeloablative Salvage Regimen for Patients with Primary Graft Failure After Allogeneic Hematopoietic Cell Transplantation
Scientists report the outcome of 11 patients with hematologic diseases (median age, 44; range, 25–67 years, seven males) who received a 1-day reduced-intensity preparative regimen given as a re-transplantation for primary graft failure. [Bone Marrow Transplant]

Classifying Cytogenetics in Patients with AML in Complete Remission Undergoing Allogeneic Transplantation: A CIBMTR Study
Researchers studied 821 adult patients reported to the CIBMTR who underwent hematopoietic cell transplantation for AML in first or second CR between 1999 and 2004. [Biol Blood Marrow Transplant]

Outcomes of Hodgkin’s Lymphoma Patients with Relapse or Progression Following Autologous Hematopoietic Cell Transplantation
In a multicenter retrospective study investigators evaluated 126 patients who relapsed/progressed after a median of 5 (1-132) months post 1st autologous hematopoietic cell transplantation. [Biol Blood Marrow Transplant]


FDA Grants TM-400 Orphan Drug Designation for Mobilization of Stem Cells Used to Treat Hematologic Cancer in the U.S.
TikoMed AB announced that the U.S. Food and Drug Administration (FDA) has granted TM-400 Orphan Drug Designation for the mobilization of stem cells prior to stem cell transplantation treatment. [TikoMed AB Press Release]

NanoString Offers New Tool for Analyzing 25 Leukemia Fusion Genes in a Single Reaction
NanoString Technologies, Inc. announced the availability of a comprehensive multiplexed assay for the simple and cost-effective analysis of fusion genes linked to leukemia. [NanoString Technologies, Inc. Press Release]


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 1st International Conference on Stem Cell Research and Applications
October 7-9, 2011
Kayseri, Turkey 

Visit our events page 
to see a complete list of events in the hematopoietic community

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Postdoc Position in Hematopoietic Stem Cells and Signaling Transduction (University of Pennsylvania School of Medicine)

Post Doctoral Fellow (MedImmune)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us